WHITEHAWK THERAPEUTICS, INC. Provision for Loan and Lease Losses
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Provision for Loan and Lease Losses of $66.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Notes
us-gaap:ProvisionForLoanAndLeaseLosses · last filed 2022-05-12
- WHITEHAWK THERAPEUTICS, INC. provision for loan and lease losses for the quarter ending 2022-03-31 was $66.00K, a 50.00% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. provision for loan and lease losses for the quarter ending 2021-12-31 was $38.00K, a 11.63% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. provision for loan and lease losses for the quarter ending 2021-03-31 was $44.00K.
- WHITEHAWK THERAPEUTICS, INC. provision for loan and lease losses for the quarter ending 2020-12-31 was $43.00K.
- WHITEHAWK THERAPEUTICS, INC. provision for loan and lease losses for fiscal 2021 was $171.00K, a 2.40% increase from fiscal 2020.
- WHITEHAWK THERAPEUTICS, INC. provision for loan and lease losses for fiscal 2020 was $167.00K.
| Period end | Provision for Loan and Lease Losses 3 month | Provision for Loan and Lease Losses 6 month | Provision for Loan and Lease Losses 9 month | Provision for Loan and Lease Losses 12 month |
|---|---|---|---|---|
| 2022-03-31 | $66.00K 10-Q · filed 2022-05-12 | $104.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2021-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $171.00K 10-K · filed 2022-03-17 | ||
| 2021-09-30 | $133.00K 10-Q · filed 2021-11-10 | |||
| 2021-03-31 | $44.00K 10-Q · filed 2022-05-12 | $87.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $167.00K 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $124.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |